TORONTO, June 03, 2024 (GLOBE NEWSWIRE) -- VitalHub Corp. (the “Company” or “VitalHub”) (TSX:VHI) (OTCQX:VHIBF), a leading provider of healthcare technology solutions, is pleased to announce a new partnership with Lumenus Community Services, a prominent Toronto-based organization dedicated to providing comprehensive support services for individuals and families. Lumenus is one of the largest providers of community services in the province, providing a single circle of care and support to their clients.
The deployment of TREAT will be instrumental in supporting their harmonization efforts by helping to standardize processes and optimize outcomes across the broad range of services provided.
This strategic partnership will leverage TREAT to improve data management, client tracking, and outcome reporting across Lumenus’ extensive range of services. The implementation of this system marks a significant step forward in Lumenus’ ongoing commitment to using technology to better serve their community.
Niels Tofting, EVP & Managing Director, North America at VitalHub expressed his enthusiasm about the partnership, stating, “We are thrilled to partner with Lumenus Community Services. This collaboration represents another opportunity for VitalHub to demonstrate TREAT’s ability to support complex care networks. We are committed to delivering solutions that not only meet but exceed the expectations of our clients, enhancing operational efficiencies and client care outcomes are of paramount importance for us.”
Christina Hoy, Corporate Services Officer, Lumenus also commented on the partnership, saying, “Our collaboration with VitalHub is a critical component of our strategic plan to utilize leading-edge technology to enhance our service delivery. The implementation of this robust electronic health record will enable us to better track and manage client data, ensuring that every individual we serve receives the best possible support tailored to their unique needs. This is about putting our clients first, and ensuring we have the best tools to do so.”
The implementation of the TREAT system at Lumenus is already underway, and this initiative is central to our efforts to support Lumenus as they navigate the challenges of unifying diverse operational cultures and practices into a cohesive framework.
ABOUT VITALHUB
Software for Health and Human Services providers designed to simplify the user experience and optimize outcomes.
VitalHub is a leading software company dedicated to empowering Health and Human Services providers. Our clients include hospitals, regional health authorities, mental health and addictions services providers for children and adults, long-term care facilities, home health agencies, correctional services, and community and social services providers.
VitalHub’s comprehensive suite of SaaS solutions include:
The Company has a robust two-pronged growth strategy, targeting organic growth opportunities within its product suite, and pursuing an aggressive M&A plan. Currently VitalHub serves more than 1,000 clients across Canada, USA, UK, Australia, the Middle East, and Europe.
VitalHub is based in Toronto, Canada, with an offshore development hub in Sri Lanka. The VitalHub team comprises more than 400 team members globally. The Company is publicly traded on the Toronto Stock Exchange (TSX) under the symbol “VHI” and on the OTC Markets OTCQX Exchange under the symbol “VHIBF”.
ABOUT LUMENUS COMMUNITY SERVICES
Lumenus Community Services offers a comprehensive range of support services aimed at promoting wellness and improving the mental health of children, youth, adults, and families in the Toronto area. Lumenus works collaboratively with clients to deliver tailored solutions that foster a supportive community environment.
CAUTIONARY STATEMENT
Certain statements contained in this news release may constitute “forward-looking information” or “financial outlook” within the meaning of applicable securities laws that involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking information or financial outlook. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “is expected”, “expects”, “scheduled”, “intends”, “contemplates”, “anticipates”, “believes”, “proposes” or variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Such statements are based on the current expectations of the management of each entity and are based on assumptions and subject to risks and uncertainties. Although the management of each entity believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and the Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.
CONTACT INFORMATION
Dan Matlow
Chief Executive Officer, Director
(416) 727-9061
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | C$10.81 |
Daily Change: | -0.12 -1.10 |
Daily Volume: | 112,898 |
Market Cap: | C$549.690M |
November 13, 2024 October 30, 2024 August 08, 2024 July 30, 2024 |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB